On Tuesday, Inspira Technologies OXY B.H.N. (NASDAQ:IINN) announced positive initial results from its previously reported collaboration with Ennocure MedTech to develop a novel bio-electronic treatment for preventing bloodstream infections.

In ex-vivo porcine skin model testing, the bio-electronic patch demonstrated a 95% reduction in bacterial presence within 4 hours, with continued effectiveness observed over 24 hours.

The technology, which uses physical electric stimulation rather than chemical agents, showed promising results in preventing pathogen growth on treated surfaces.

Also Read: Monday.com Beats Q4 Earnings Estimates, Boasts 32% Revenue Growth: CEO Calls AI A Game-Changer

Inspira Technologies chief Dagi Ben-Noon noted an estimated 250,000 bloodstream infections related to intravenous lines occurring worldwide yearly. The approach could offer significant advantages in critical care settings.

Bio-electronic technology can address several key challenges associated with traditional IV dressings, including prevention of bacterial growth through physical rather than chemical means, potential for extended wear time, reduced frequency of dressing changes, applicability to both skin surface and cannula areas, and real-time monitoring capabilities.

Price Action: IINN stock is down 3.35% at $0.8206 premarket at last check on Tuesday.

Also Read:

• Tower Semiconductor Q4 Earnings: Beats EPS Estimates, Expands AI Chip Production For 2025 Growth, Stock Falls As Outlook Disappoints The Street

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article EXCLUSIVE: Inspira and Ennocure's Bio-Electronic Tech Uses Electric Stimulation to Help Prevent IV-Related Infections originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.